Wang Shifen, Zhao Xingyun, Wu Siwen, Cui Dawei, Xu Zhenshu
Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Biomark Res. 2023 Mar 29;11(1):34. doi: 10.1186/s40364-023-00475-8.
The immunosuppressive tumor microenvironment (TME) supports the development of tumors and limits tumor immunotherapy, including hematological malignancies. Hematological malignancies remain a major public health issue with high morbidity and mortality worldwide. As an important component of immunosuppressive regulators, the phenotypic characteristics and prognostic value of myeloid-derived suppressor cells (MDSCs) have received much attention. A variety of MDSC-targeting therapeutic approaches have produced encouraging outcomes. However, the use of various MDSC-targeted treatment strategies in hematologic malignancies is still difficult due to the heterogeneity of hematologic malignancies and the complexity of the immune system. In this review, we summarize the biological functions of MDSCs and further provide a summary of the phenotypes and suppressive mechanisms of MDSC populations expanded in various types of hematological malignancy contexts. Moreover, we discussed the clinical correlation between MDSCs and the diagnosis of malignant hematological disease, as well as the drugs targeting MDSCs, and focused on summarizing the therapeutic strategies in combination with other immunotherapies, such as various immune checkpoint inhibitors (ICIs), that are under active investigation. We highlight the new direction of targeting MDSCs to improve the therapeutic efficacy of tumors.
免疫抑制性肿瘤微环境（TME）支持肿瘤的发展，并限制肿瘤免疫治疗，包括血液系统恶性肿瘤。血液系统恶性肿瘤仍然是一个主要的公共卫生问题，在全球范围内发病率和死亡率都很高。作为免疫抑制调节因子的重要组成部分，髓源性抑制细胞（MDSCs）的表型特征和预后价值受到了广泛关注。多种针对MDSCs的治疗方法已经取得了令人鼓舞的成果。然而，由于血液系统恶性肿瘤的异质性和免疫系统的复杂性，在血液系统恶性肿瘤中使用各种针对MDSCs的治疗策略仍然很困难。在这篇综述中，我们总结了MDSCs的生物学功能，并进一步概述了在各种类型的血液系统恶性肿瘤背景下扩增的MDSC群体的表型和抑制机制。此外，我们讨论了MDSCs与恶性血液病诊断之间的临床相关性，以及针对MDSCs的药物，并重点总结了与其他免疫疗法（如各种免疫检查点抑制剂（ICIs））联合使用的治疗策略，这些策略正在积极研究中。我们强调了靶向MDSCs以提高肿瘤治疗疗效的新方向。
